a r t i c l e s
The FH1-4-C3b interaction has been well characterized 14 ( Fig. 1) , but the FH19-20-C3b interaction has not. This is despite the presence in the factor H C terminus of a mutation cluster linked to the kidney disease aHUS [15] [16] [17] together with a polyanionbinding site that is required for self-surface recognition by factor H 18, 19 . These two C3b-binding sites of factor H confer avidity 12 , but the role of the intervening 14 CCPs remains controversial. CCP7 contains a second polyanion-binding site 12, 16, 20, 21 and harbors the SNP that is most strongly linked to the risk of developing age-related macular degeneration [22] [23] [24] [25] .
How these multiple binding sites for C3b and polyanions, located toward either end of the 20-CCP length of factor H, cooperate to engage with C3b preferentially on a GAG-rich self surface remains a mystery. This dearth of knowledge impedes our understanding of the roles of factor H mutants and sequence variants in disease. Here we show that an atomic-resolution crystal structure of the C3d-FH19-20 complex emulates the interaction between the factor H C terminus and C3b. We have combined this structure with further experimental data to build a model of the complex formed by factor H with C3b tethered to a self surface.
RESULTS

The crystal structure of C3d-FH19-20 at 2.1 Å resolution
We obtained useable co-crystals of C3d and FH19-20 at pH 7.0 and pH 9.0. In both cases the asymmetric unit contained three molecules each of FH19-20 and C3d. Although crystal packing was not identical, the two crystal structures contained similar intermolecular interactions ( Supplementary Fig. 1 ). The higher-pH structure had better resolution (2.1 Å versus 3.5 Å; Table 1 ) and is discussed further.
We observed eight sets of heterotypic contacts between FH19-20 molecules and C3d molecules in the crystal structure ( Supplementary  Fig. 1 and Supplementary Tables 1 and 2), with the two most extensive sets being nearly identical. This duplicated interface-unlike others in the crystal structure-could correspond to the physiologically crucial interface between the factor H C terminus and C3b. FH19-20 does not experience any steric clashes when this interface is extrapolated onto the corresponding TED domain of C3b (as judged from the multiple crystal structures of C3b 3, 14, 26 ; Supplementary Fig. 2 ), nor would it sterically hinder the functionally crucial covalent linkage of C3d to biological surfaces, centered around Gln20 (Gln1013; prepro-C3 numbering indicated in parentheses). This interface also correlated well with the distribution of a number of disease-associated variants of factor H and C3 (discussed below). The alternative complexes that might be inferred from other, less extensive candidate interfaces in the crystal structure (Supplementary Tables 1 and 2) could not occur in the complex of factor H with surface-bound C3b as they would involve substantial steric clashes between FH19-20 and C3b or would mask the residues involved in surface tethering Figure 1 Introduction to C3b/C3d and complement factor H. (a) The central event in complement activation is the cleavage of C3 to C3b by C3 convertase, accompanied by attachment to surfaces mediated by the TED. In the presence of additional complement regulatory molecules, C3b may be further degraded sequentially to iC3b, C3c, C3dg and C3d. C3d corresponds to the TED and remains bound to the cell surface. (b) Complement factor H has 20 CCPs and multiple binding sites for different ligands. Disease-linked mutations have been reported throughout factor H. Several recombinant fragments of factor H were used in the current studies and are indicated by black brackets. FD, factor D; FI, factor I; DAF, decayaccelerating factor; CR1, complement receptor type 1; CUB, complement C1r-C1s; UEGF, urinary epidermal growth factor; BMP1, bone morphogenetic protein 1. a r t i c l e s ( Supplementary Fig. 2) . Moreover, the distributions of disease-associated mutations in factor H and C3 are inconsistent with the alternative interfaces. We describe further experimental validation of the physiologically relevant C3d-FH19-20 complex below. Our structure confirms that discontinuous stretches of the FH19-20 polypeptide form a contiguous binding surface for C3d (Fig. 2a,b and Supplementary Fig. 1 ) that buries ~750 Å 2 of surface. The C-terminal half of C3d α-helix 4 (α4) contacts a region centered on β-strand B (βB) of factor H CCP19 that also includes the hypervariable region after βB, the C-terminal part of βD and the early part of the βD-βE loop. The α4-α5 loop of C3d protrudes, occupying the cleft between the two factor H CCPs. Its side chains contact βC in CCP20 as well as the intermodular linker. There is also substantial burial in the intermolecular interface of Tyr1190 (in CCP20) and van der Waals interactions between intermodular linker residue Pro1166 and C3d-residue Prol121 (Pro1114 in C3). The N-terminal half of C3d α7 also participates: Lys178 (Lys1171) forms hydrogen bonds with CCP19 residues Asn1117 and also with Gln1139 and Tyr1142 of the CCP19 βD-βE loop. Thus a network of side chain-backbone and side chain-side chain hydrogen bonds and van der Waals contacts (Fig. 2c,d and Supplementary Fig. 1 ) stabilizes the intermolecular interface that involves modules 19 and 20 of FH.
NMR confirms C3d-interaction regions of FH19−20
We used NMR spectroscopy to independently investigate the C3d-FH19-20 complex. When we added (non-isotopically labeled) C3d, there was a marked reduction in amide NH signal intensities in the 1 H, 15 N-HSQC spectrum of [ 15 N]FH19-20 ( Fig. 3; Supplementary  Fig. 3 ). This reflects formation of the C3d-FH19-20 complex, which 27, 28 ; it occurs for amides that show larger chemical shift differences between bound and free forms. Corresponding residues probably contribute directly to binding or participate in conformational changes upon binding 29, 30 . Eleven cross-peaks that were originally present in the [ 15 N]FH19-20 spectrum were broadened upon addition of C3d to the extent that they lost more than 90% of their signal intensities ( Fig. 3 and Supplementary Fig. 3 ). Mapping the positions of these most strongly affected amides on the FH19-20 structure (Fig. 3) provided strong evidence for the C3d-binding surface identified in the crystal structure. In CCP19, βB (including Asp1119) and the first few residues of the βB-βC hypervariable loop plus the end of βD are implicated; in CCP20, βC appears to be involved. Only Tyr1177 and Ser1209 (whose signal loss was just above the 90% threshold) lie outside this interaction region.
Mutagenesis studies of the C3d-FH19-20 binding interface
We combined new and existing mutagenesis data to corroborate our structural findings. Using surface plasmon resonance, we tested functionally critical mutations in the structure of FH19-20 (ref. 31 ; Fig. 4a-d) .
The factor H mutation that had the most deleterious effect on the binding of factor H to C3d and C3b, which also abrogated activity in a hemolysis-protection assay, was D1119G in CCP19 (Fig. 4c-e and Supplementary Figs. 4 and 5) ; this is consistent with its key position in the interface identified from NMR and X-ray crystallography. A second key interface residue, according to our X-ray crystallographic structure, is Gln1139 of CCP19; in a previous mutagenesis study the Q1139A mutant of FH19-20 showed greatly reduced capacity to inhibit binding of wild-type factor H to C3d 32 . Other functionally relevant mutations occupy several faces of CCP20 but do not appear to delineate a discrete binding surface (Fig. 4d-f) .
We also measured affinities between selected FH19-20 mutants and five C3d mutants ( Fig. 4g and Supplementary Fig. 4 ): E117A (E1110A), D122A (D1115A) and E117A D122A (E1110A D1115A) occupy the interface derived from NMR and crystallography, whereas E160A (E1153A) and I164A (I1157A) occur in the 'concave' surface of this molecule away from the putative FH19-20 binding site. Our E117A D122A (E1110A D1115A) double mutation resulted in a decrease in affinity by a factor of ~1,600 (Supplementary Table 3 and Supplementary Fig. 4) . With regard to single mutants, in general (and with the exception of the aforementioned D1119G), loss of a positive charge in FH19-20 or loss of a negative charge in C3d decreased affinity, even away from the binding interface. However, it is noteworthy that the C3d single-site E117A (E1110A) and D122A (D1115A) mutations attenuated FH19-20 binding by a factor of 2 or 3 when compared to E160A and to the non-charge substitution I164A, and by a factor of 4-6 when compared to wild-type C3d (Supplementary Table 3) .
Mutagenesis studies therefore confirmed that Glu117 (Glu1110) and Asp122 (Asp1115) in C3d and Asp1119 and Gln1139 in CCP19 were key interface residues. Other charged residues investigated here presumably participate in electrostatic steering effects. Such longrange charge effects have been reported for the interactions that occur between C3d and CR2 and between C3d and the staphylococcal immune evasion molecule Efb-C 33, 34 .
Mutagenesis justifies extrapolation to C3b-F19-20 complex
We investigated whether structural information concerning the C3d-FH19-20 complex could be extrapolated to the physiologically important C3b-FH complex. We measured affinities for C3d (and, in some cases, for C3b) of FH15-19, FH18-20, FH19-20 and a panel of FH19-20 mutants ( Supplementary Fig. 4 and Supplementary Table 3) . FH18-20 and FH19-20 had similar affinities for C3d (Fig. 4a,b,d and  Supplementary Table 3) . Moreover, both bound equally well to C3b (Fig. 4d  and Supplementary Fig. 4 ). Thus we confirmed that both the C3b-FH and C3d-FH interfaces involved CCP19 and CCP20 (consistent with ref. 35 ) but not CCP18. Each of these FH19-20 mutants bound similarly well, or similarly poorly, to both C3d ( Fig. 4d and  Supplementary Fig. 4 ) and C3b (based on dissociation constant (K D ) values reported in ref. 31 ). FH19-20 D1119G bound to neither of these C3 fragments 31 (Fig. 4c) . A comparison of the mutagenesis data (Fig. 4e,f) illustrates that the C3d-FH19-20 interface must emulate the interface between the C terminus of factor H and C3b. A logical extension of this finding is that the site in C3d that interacts with FH19-20 must correspond to an accessible face of the TED in C3b. As outlined above, this requirement is met by the C3d-FH19-20 interface identified by both NMR and crystallography.
The good superposition of the C3d polypeptide in the C3d-FH19-20 complex onto the relevant residues of the TED domain in the crystal structure of the C3b-FH1-4 complex (PDB accession code: 2WII 14 ) is shown in Figure 5 . The resulting merged model of a ternary complex of C3b with two segments of factor H suggested that CCP19 of FH19-20 lay immediately adjacent to CCP4 of FH1-4 but that the two fragments occupied distinct regions of C3b, consistent with simultaneous binding. The merged model also suggested that, in the complex, the majority of CCP20 was exposed and positioned to interact with polyanionic surface markers.
NMR identifies GAG-binding site in C3d-FH19-20 complex
We carried out experiments to ascertain whether CCP20 in the C3d-FH19-20 complex could still engage with model GAGs (surrogates for self-surface markers) and to identify which residues of factor H were crucial for binding GAG.
In initial benchmarking work, we titrated an octasaccharide fraction of heparin, dp8, into 15 N-labeled FH19-20 (no C3d present; Supplementary Fig. 3 ). The largest chemical-shift changes (brought about by an 8.5:1 ratio of dp8-FH19-20; Fig. 3c ) occurred in residues that belonged to CCP20. The distribution of affected residues (Fig. 5) was consistent with two (or more) dp8 molecules binding with similar affinities to electropositive patches around Lys1186-Lys1188 and Arg1231; this agrees with the results of an NMR study on FH19-20 performed with a tetrasaccharide heparin fragment 16 .
Titration with up to a 15-fold excess of dp8 into the C3d-[ 15 N]FH19-20 complex caused chemical shift changes but did not alter spectral intensities or line widths (Supplementary Fig. 3) . In separate experiments, a 20-fold excess (over FH19-20) of a pentasaccharide GAG (Fondaparinux) did not inhibit binding of FH19-20 to amine-coupled C3d according to surface plasmon resonance (SPR; Supplementary Fig. 4) ; furthermore, molar excesses of up to 200-fold (over C3d) of dp8 failed to inhibit binding of C3d to FH19-20 in an ELISA-based assay (Supplementary Fig. 6 ). All these experiments supported the existence of a ternary (or higher order) complex between C3d, FH19-20 and GAGs.
The subset of FH19-20 NH resonances that experienced substantial dp8-induced chemical shift changes was essentially the same whether FH19-20 was in complex with C3d or not ( Supplementary  Fig. 3b,c) . The amide resonances of some CCP20 residues (exemplified by Lys1188) that have been implicated in C3d binding remain weak when GAGs are added, consistent with C3d proximity; but they still show GAG-associated chemical-shift perturbations similar to those observed in the absence of C3d, which is consistent with GAG binding and ternary complex formation. Although there might be a mixture of binary and tertiary complexes in the NMR tube, we can nevertheless conclude that at least one dp8 molecule binds to the C3d-FH19-20 complex at a region of CCP20 that is distinct from the C3d-binding site (Fig. 5) and proximal to the surface to which C3d-TED is tethered. Our data are consistent with previous studies in which K1186A, K1188A, K1188Q, L1189R and K1230A FH19-20 mutants, among others, were shown to have altered heparin affinity 31 
a r t i c l e s
Factor H bends back to allow both termini to interact with C3b
In the modeled ternary complex of C3b, FH1-4 and FH19-20, the C terminus of CCP4 and the N terminus of CCP19 lay close together on the same side of C3b, but importantly, did not clash (Fig. 5a-c) . This was consistent with a 1:1 complex of C3b and factor H in which intervening factor H CCP modules form a compact bentback structure (Fig. 5b) , or with a 1:2 FH-C3b complex in which a more extended single factor H molecule bridges two C3b molecules.
To complement the incomplete experimental evidence on factor H architecture [36] [37] [38] , we collected small-angle X-ray scattering (SAXS) curves for FH1-4, FH8-15 and FH15-19, and performed ab initio shape calculations ( Fig. 5b and Supplementary Fig. 7) . The resulting ab initio model of FH1-4 agreed well with the corresponding crystal structure 14 , whereas the FH8-15 and FH15-19 shape envelopes (for which no structures are available) described a relatively compact bent-back structure and an extended rod-like structure, respectively. The compact shape of the FH8-15 model (as described for both FH10-15 and FH11-14) 37 involved substantial intermodular contacts that could stabilize bent-back structures for both free and C3b-bound full-length factor H. By manually concatenating our SAXS-derived envelopes for FH8-15 and FH15-19 with the X-ray-derived structures of FH6-8 36 and C3d-FH19-20, we could model factor H modules 6-20 in complex with C3b (Fig. 5b) . This model was readily adjusted so that CCP6 and the C terminus of CCP4 (in the C3b-FH1-4 complex overlaid by TED on C3d) were separated by a space large enough to be spanned by the known structure of CCP5 39 , thereby creating a model of a 1:1 C3b-FH complex.
DISCUSSION
Our results have shed light on how factor H binds to its principal target. This crucial event in regulation of C3b promulgation on self surfaces is essential for protection of host tissues from complementmediated damage. Building on previous indications that FH19-20 binds to both C3b and the C3b-derived fragment C3d 32 , we have shown that the C3d-FH19-20 interaction is a surrogate for the less experimentally accessible FH-C3b interaction. Our findings, when combined with published data, show how the factor H molecule bends back on itself so that its N terminus performs cofactor and decay accelerating activities while its C terminus recognizes a composite consisting of the TED of C3b and nearby polyanionic carbohydrates. This allows a self surface to be distinguished from most bacterial ones.
Mindful of controversy surrounding the physiological validity of a crystal structure of C3d complexed with CR2 CCP1-2 (ref. 40) , we used mutagenesis and NMR to select the physiologically relevant intermolecular interface from several possibilities in our crystal structure of C3d-FH19-20. Moreover, this interface of C3d was consistent with other observations. (i) It is accessible in TED (in the context of C3b) tethered to a surface; moreover, the orientation of FH19-20 means that CCP18 is projected clear of C3b, consistent with our finding that it binds neither C3d nor C3b ( Supplementary Fig. 4 and Supplementary Table 3 ). (ii) It does not overlap the FH1-4 interaction site on C3b 14 , consistent with avidity between sites 12 . (iii) It is directly adjacent to (but does not overlap) the Efb-C-binding site 41 ( Supplementary  Fig. 8) ; this is relevant because Efb-C enhances binding of C3b to FH19-20 42 . (iv) The C3d and factor H residues that are involved are conserved (Supplementary Fig. 9 ).
We confirmed that previously identified GAG-binding residues of CCP20 are still accessible in this complex. This is strong structural evidence for the hypothesis that FH19-20 interacts with a composite site consisting of the TED and proximal polyanions. Previous attempts to dock C3d onto the surface of FH19-20 have been unsuccessful 16, 43 . In both of these models of C3d-FH19-20, only CCP20 makes contact with C3d; moreover, the interfaces on C3d differ from those identified in our co-crystal structure.
Our data reveal the locations, relative to key interaction surfaces, of disease-linked mutations and sequence variations (Fig. 6) . The structure explains the key role in C3b binding of the disease-linked mutation D1119G, despite suggestions from others that this mutation is functionally null 32 . Our complex also shows that the following aHUSlinked factor H mutations 44 affect the C3d-FH19-20 interface and thereby perturb the fine balance of affinities needed for proper factor H operation: Y1142D and Y1142C, as Tyr1142 hydrogen bonds to Lys178 (K1171) of C3d; Q1143E, owing to its proximity to Tyr1142; and L1189F, L1189R and S1191L, as Tyr1190 hydrogen bonds to Asp122 (Asp1115) of C3d and is partially buried at the interface. Other aHUS-linked factor H mutations are in the GAG-binding regions of CCP20 or could disrupt putative electrostatic steering events (E1198A, R1203A, R1210C, R1215G, R1182S, W1183R and T1184R). Another subset of aHUS-linked factor H mutants probably promotes structural perturbations (W1157R, V1134G, G1194D, V1197A, F1199S and P1226S). Regarding the C3b side of the interaction, the following aHUS-linked mutations probably disrupt the binding interface: P121L (P1114L) 45 and D122N (D1115N) 46 are in the C3d α4-α5 loop that occupies the FH19-20 intermodular cleft; and C165W (C1158W) and Q168K (Q1161K) 46 are in the C3d α6-α7 loop that coincides with closest approach of the N-terminal and C-terminal C3b-binding sites of factor H (Fig. 5c) .
In a previously solved structure of the FH1-4-C3b complex 14 , the four N-terminal CCPs of factor H form an elongated contact with C3b running largely parallel to the long axis of C3b. If C3b in this complex were attached to the surface by its thioester, CCP1 would be furthest from and CCP4 closest to that surface. In other regulators of the alternative pathway, a similar three-CCP or four-CCP C3b-binding segment is connected to a C-terminal transmembrane helix or a glycosylphosphatidylinositol anchor, which localizes the regulator on a a r t i c l e s cell surface that requires protection from C3b promulgation. Factor H is not constrained to a membrane but relies on some or all of its C-terminal 16 CCPs for localization, and exploits the preponderance of polyanionic self-surface markers to selectively increase its residence on self surfaces. We investigated the path taken by CCPs 5-18, which connect N-terminal and C-terminal C3b-binding sites, to construct an experimentally derived model of the FH-C3b complex.
When we superimposed the C3d of C3d-FH19-20 on the TED of C3b, the FH1-4 C terminus and FH19-20 N terminus were close together. A bent-back factor H structure would therefore be required for a single molecule to simultaneously occupy both sites on C3b (and to interact with self-surface associated polyanions), as in our model (Fig. 5a) . This is consistent with our SAXS-derived shape envelopes of factor H fragments, as well as with existing SAXS, crystal and NMRderived structures, and agrees with work showing that non-liganded factor H could adopt a predominantly bent-back conformation 37, [47] [48] [49] [50] . Our data are incompatible with an alternative model in which factor H wraps around the C3b molecule. However, we cannot exclude the possibility of a complex in which one factor H molecule binds to two neighboring, closely packed C3b molecules.
Previous studies suggested that there was a weak additional C3b-binding site in CCPs 6-8 of factor H 12,13 . Although our model contains no such interface, uncertainties in reconstruction of the N-terminal half of factor H (a lack of structural information for FH4-5 and FH5-6) means that we cannot rule out contacts between CCP6 or 7 and C3b. Nonetheless, our model places CCP7 close to the self surface where it could recognize additional GAG surface markers; it also places the structurally deviant module CCP13 (ref. 37) close to the self surface, although the nature of any ligand for CCP13 remains undetermined.
In summary, we have presented an experimentally supported structural model for how a factor H molecule engages bivalently with a C3b molecule and simultaneously with self-surface polyanionic markers. The model indicates that effective complement inhibitors, with therapeutic potential, might be constructed through flexible linkage of FH19-20, through a domain with appropriately apposed N and C termini, to FH1-4 or homologous segments of other complement regulators. 
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